The global Hematopoietic Stem Cell Transplantation (HSCT) Market, by Transplant Type [(Allogeneic and Autologous), by Indication (Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Hodgkin lymphoma (HL), Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), and Other Disorders)], by Application [(Bone Marrow Transplant (BMT), Peripheral Blood Stem Cells Transplant (PBSCT), and Cord Blood Transplant (CBT)], by End User (Hospitals, Specialty Clinics and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 2.88 Billion in 2023 and is expected to exhibit a CAGR of 11.2% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
The increasing research and development activities by key market players are expected to drive market growth over the forecast period. For instance, in October 2020, Gamida Cell Ltd., a company providing cell therapies, announced that the Phase 3 study of omidubicel, an investigational advanced cell therapy in development, is a potentially life-saving treatment option for patients in need of a bone marrow transplant and also met all three of its secondary endpoints. In addition, increasing positive activities by the public and private sectors toward bone marrow transplants are also anticipated to surge segment growth.
Global Hematopoietic Stem Cell Transplantation (HSCT) Market – Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others, faced problems with regard to the transportation of things from one place to another.
COVID-19 had a negative impact on the global hematopoietic stem cell transplantation (HSCT) market owing to slow growth during the pandemic as the treatment of leukemia was delayed in many countries. For instance, according to the study titled "COVID-19 infection in patients with acute leukemia: Istanbul experience," published in August 2021, the proper management of acute leukemia is necessary as it may lead to death if it is not treated promptly. This became a challenge during the pandemic. In addition, several guidelines were also published to decrease mortality in acute leukemia patients. Moreover, it also stated that the management of leukemia patients with COVID-19 infection was also very challenging during the pandemic. Hematopoietic stem cell transplantation is one of the most effective treatments for leukemia. Therefore, such instances indicate that the market witnessed a slow growth rate during the pandemic.
Global Hematopoietic Stem Cell Transplantation (HSCT) Market: Key Developments
On April 17, 2023, Gamida Cell Ltd. announced the U.S. Food and Drug Administration (FDA) approval for Omisirge (omidubicel-onlv), an allogenic cell therapy to reduce the risk of infection in blood cancer patients. Omisirge works by speeding the recovery of neutrophils, a type of white blood cell that combats infection. Specifically, the drug is approved for patients 12 and older who are undergoing umbilical cord blood transplantation following radiation or chemotherapy.
On March 9, 2023, Astellas Pharma Inc., a pharmaceutical company, and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), conducts large, multi-institutional trials, announced topline results from the Phase 3 MORPHO clinical trial evaluating gilteritinib as a maintenance therapy following allogeneic hematopoietic stem cell transplantation (HSCT) for patients with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) mutated acute myeloid leukemia (AML).
In May 2022, Priothera, a late-clinical-stage biotechnology company pioneering the development of its S1P receptor modulator compound, mocravimod, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) for mocravimod in combination with allogeneic hematopoietic stem cell transplant (HSCT) for post-remission therapy of acute myeloid leukemia (AML) patients.
Browse 38 Market Data Tables and 33 Figures spread through 225 Pages and in-depth TOC on “Global Hematopoietic Stem Cell Transplantation (HSCT) Market ”- Forecast to 2030, Global Hematopoietic Stem Cell Transplantation (HSCT) Market, by Transplant Type [(Allogeneic and Autologous), by Indication (Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Hodgkin lymphoma (HL), Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), and Other Disorders)], by Application [(Bone Marrow Transplant (BMT), Peripheral Blood Stem Cells Transplant (PBSCT), and Cord Blood Transplant (CBT)], by End User (Hospitals, Specialty Clinics and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).
To know the latest trends and insights prevalent in this market, click the link below:
Key Takeaways of the Global Hematopoietic Stem Cell Transplantation (HSCT) Market:
- The global hematopoietic stem cell transplantation (HSCT) market is expected to exhibit a CAGR of 2% during the forecast period. The increasing approval of research activities by regulatory authorities is expected to drive market growth over the forecast period. For instance, in April 2022, Priothera Ltd. announced that it had received the two first European country approvals from the Swiss and French national health authorities (Swissmedic and ANSM) to begin its planned pivotal study of mocravimod. The company has also received encouraging feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) on the clinical study design, which is closely aligned with earlier feedback from the US Food and Drug Administration (FDA).
- Among application, the bone marrow transplant (BMT) segment is expected to hold a dominant position in the global hematopoietic stem cell transplantation (HSCT) market during the forecast period, and this is attributed to the increasing number of bone marrow transplantation procedures. For instance, on June 13, 2023, according to data provided by the Health Resources and Services Administration, an agency of the U.S. Department of Health and Human Services, in 2021, 5,073 unrelated and 4,276 related bone marrow and cord blood transplants were performed in the U.S. Of these, 5,073 (22%) were unrelated transplants, and 4,276 (19%) were related transplants.
- Among transplant type, autologus segment is expected to hold a dominant position in the global hematopoietic stem cell transplantation (HSCT) market during the forecast period, and this is attributed to the increasing inorganic growth strategies such as acquisitions by key market players to expand their product portfolio. For instance, on June 30, 2023, Baudax Bio, Inc., a pharmaceutical company focused on innovative products for acute care, announced the acquisition of TeraImmune, a privately held biotechnology company focused on the discovery and development of novel Treg-based cell therapies for autoimmune diseases. This acquisition adds TeraImmune’s TI-168 asset to the Baudax portfolio, a promising next-generation, autologous FVIII TCR-Treg cell therapy candidate to eliminate clotting factor VIII (FVIII) inhibitors in Hemophilia A patients.
- Among region, North America is expected to be the dominant region in the global hematopoietic stem cell transplantation (HSCT) market owing to factors such as rising cases of leukemia and increasing investment in research and development by the public and private sectors. For instance, as per the data published by the Canadian Cancer Society in May 2022, it was estimated there would be 6,700 new cases of leukemia in Canada (excluding Quebec) and 3,100 leukemia deaths. Stem cell transplants help with leukemia by allowing the body to replace damaged blood cells with healthy ones. Hematopoietic stem cells help with leukemia by allowing the body to replace damaged blood cells with healthy ones. Stem cells can turn into many other types of cells. Therefore, increasing cases of leukemia are expected to propel the demand for hematopoietic stem cell transplantation, thereby propelling market growth over the forecast period.
- Major players operating in the global hematopoietic stem cell transplantation (HSCT) market are Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Inc., Talaris Therapeutics, Inc., Marker Therapeutics Inc., Stempeutics Research Pvt Ltd., CBR Systems Inc., Priothera Ltd., Eurobio Scientific Group, Otsuka America Pharmaceutical, Inc., Pfizer Inc., Sanofi, and FUJIFILM Holdings Corporation
